Table of Contents
Chemotherapy
Following surgery, patients (other than those with early-stage, low-grade disease) usually have chemotherapy. Unlike surgery and radiation, which treat the cancerous tumor and the area surrounding it, drug therapy destroys rapidly dividing cells throughout the body, so it is a systemic therapy.
Ovarian cancers are very sensitive to chemotherapy and often respond well initially. Unfortunately, in most cases, ovarian cancer recurs. With treatment advances, however, more than half of women now survive 5 years or longer. Doctors are now approaching this disease as a chronic and potentially long-term illness that requires the following:
- Identifying the disease recurrence as soon as possible
- Administering treatments that are as effective as possible without causing suffering
- Partnering with the patient in determining her own best course
Drugs Used in Chemotherapy
Standard Chemotherapy. The standard initial chemotherapy uses a combination of:
- A platinum-based drug, such as carboplatin (Paraplatin) or cisplatin (Platinol). Carboplatin is preferred over cisplatin in the combination. Carboplatin works as well as cisplatin but is less toxic and can be administered in a more convenient, outpatient regimen.
- A taxane, such as paclitaxel (Taxol) or docetaxel (Taxotere). Currently, paclitaxel is the drug most often used as initial therapy in combination with a platinum drug.
Chemotherapy for Relapsed or Refractory Cancer. Unfortunately, even in patients who respond, the disease eventually becomes resistant to the first-line drugs, and the cancer returns. Some ovarian tumors are resistant to platinum drugs.
Once cancer recurs or continues to progress, the patient may be treated with more cycles of carboplatin and a taxane drug, or a different type of chemotherapy drug may be used in combination treatment.
Previous Section
Review Date: 11/04/2010
Reviewed By: Harvey Simon, MD, Associate Professor of Medicine, Harvard Medical
School; Physician, Massachusetts General Hospital. Also reviewed by
David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org)
